checkAd

     121  0 Kommentare Millendo Therapeutics Announces Proposed Public Offering of Common Stock - Seite 3

    New factors emerge from time to time and it is not possible for Millendo to predict all such factors, nor can Millendo assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to Millendo as of the date of this press release. Millendo disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

    Lesen Sie auch

    Seite 3 von 3




    Business Wire (engl.)
    0 Follower
    Autor folgen

    Millendo Therapeutics Announces Proposed Public Offering of Common Stock - Seite 3 Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, today announced that it has commenced an underwritten public offering of shares of its common …